In this episode of the Oncology Brothers podcast, we had the privilege of hosting Dr. Thor Halfdanarson from the Mayo Clinic, a world-renowned expert in neuroendocrine tumors (NETs). We delved into the complexities of diagnosing and treating these unique tumors, emphasizing the importance of understanding their origin, grade, and functional status.
Dr. Halfdanarson laid a solid foundation by discussing the critical aspects of initial workup, including the significance of Ki-67 and the necessity of high-quality imaging, such as dual or triple-phase CT scans and DOTATATE PET scans, to detect metastatic disease. We explored the treatment paradigms for both functional and non-functional NETs, highlighting the dual goals of managing symptoms and controlling tumor growth.
A significant portion of our conversation focused on somatostatin analogs and their role in symptom management, as well as the emerging data from the NETTER studies regarding radioligand therapy with lutetium. Dr. Halfdanarson provided insights into the nuances of treatment sequencing, particularly when considering therapies like Everolimus, Capecitabine, and Cabozantinib, while also addressing the importance of monitoring patients through conventional imaging and tumor markers.
We wrapped up with rapid-fire questions covering topics such as the role of next-generation sequencing in NETs, the potential for immunotherapy in high-grade neuroendocrine carcinomas, and the appropriate starting dose for Cabozantinib. Dr. Halfdanarson emphasized the value of multidisciplinary care and the importance of clinical trials in advancing our understanding and treatment of neuroendocrine tumors.
Overall, this episode was packed with valuable information for community oncologists and healthcare providers, and we hope our listeners found it as enlightening as we did.
